Atezolizumab induced immune-related adverse event mimicking conjunctival metastatic disease

PURPOSE: To describe a case of an immune-related adverse event associated with Atezolizumab therapy which was aggravated by ocular surgery. OBSERVATIONS: A 59-year-old man treated with Atezolizumab for metastatic non-small-cell lung cancer developed a conjunctival hypertrophic lesion mistaken for me...

Descripción completa

Detalles Bibliográficos
Autores principales: Aschauer, Julia, Donner, Ruth, Lammer, Jan, Schmidinger, Gerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933674/
https://www.ncbi.nlm.nih.gov/pubmed/35313472
http://dx.doi.org/10.1016/j.ajoc.2022.101489
Descripción
Sumario:PURPOSE: To describe a case of an immune-related adverse event associated with Atezolizumab therapy which was aggravated by ocular surgery. OBSERVATIONS: A 59-year-old man treated with Atezolizumab for metastatic non-small-cell lung cancer developed a conjunctival hypertrophic lesion mistaken for metastatic tissue. Biopsy surgery induced fulminant and multifocal granulomatous conjunctival tissue growth and sterile corneal ulceration. The immune-related adverse event was refractory to topical therapy, with curative success only after introduction of systemic prednisone. CONCLUSIONS: Atezolizumab use may be associated with severe and recalcitrant ocular surface inflammation with potential exacerbation after surgical interventions.

Ejemplares similares